Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
Sign Up to like & getrecommendations! Published in 2018 at "Osteoporosis International"
DOI: 10.1007/s00198-018-04821-7
Abstract: SummaryThe use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in… read more here.
Keywords: alendronate generic; treatment; risedronate treatment; risedronate ... See more keywords
Abaloparatide: First Global Approval
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0780-7
Abstract: Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis. Abaloparatide acts through selective activation of the… read more here.
Keywords: abaloparatide first; global approval; treatment postmenopausal; first global ... See more keywords
Long-Term Treatment of Postmenopausal Osteoporosis
Sign Up to like & getrecommendations! Published in 2021 at "Endocrinology and Metabolism"
DOI: 10.3803/enm.2021.301
Abstract: Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do… read more here.
Keywords: treatment postmenopausal; postmenopausal osteoporosis; term treatment; long term ... See more keywords